Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;50(7): e5920, 2017. graf
Artículo en Inglés | LILACS | ID: biblio-951704

RESUMEN

As an active constituent of the beetle Mylabris used in traditional Chinese medicine, cantharidin is a potent and selective inhibitor of protein phosphatase 2A (PP2A) that plays a crucial role in cell cycle progression, apoptosis, and cell fate. The role and possible mechanisms exerted by cantharidin in cell growth and metastasis of breast cancer were investigated in this study. Cantharidin was found to inhibit cell viability and clonogenic potential in a time- and dose-dependent manner. Cell cycle analysis revealed that cell percentage in G2/M phase decreased, whereas cells in S and G1 phases progressively accumulated with the increasing doses of cantharidin treatment. In a xenograft model of breast cancer, cantharidin inhibited tumor growth in a dose-dependent manner. Moreover, high doses of cantharidin treatment inhibited cell migration in wound and healing assay and downregulated protein levels of major matrix metalloproteinases (MMP)-2 and MMP-9. MDA-MB-231 cell migration and invasion were dose-dependently inhibited by cantharidin treatment. Interestingly, the members of the mitogen-activated protein kinase (MAPK) signaling family were less phosphorylated as the cantharidin dose increased. Cantharidin was hypothesized to exert its anticancer effect through the MAPK signaling pathway. The data of this study also highlighted the possibility of using PP2A as a therapeutic target for breast cancer treatment.


Asunto(s)
Humanos , Animales , Femenino , Conejos , Neoplasias de la Mama/tratamiento farmacológico , Cantaridina/farmacología , Transducción de Señal/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Antineoplásicos/farmacología , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Ensayos de Selección de Medicamentos Antitumorales , Movimiento Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;49(12): e5826, 2016. graf
Artículo en Inglés | LILACS | ID: biblio-828173

RESUMEN

Glucagon-like peptide 1 (GLP-1), a kind of gut hormone, is used in the treatment of type 2 diabetes (T2D). Emerging evidence indicates that GLP-1 has anti-inflammatory activity. Chronic inflammation in the adipose tissue of obese individuals is a cause of insulin resistance and T2D. We hypothesized that GLP-1 analogue therapy in patients with T2D could suppress the inflammatory response of macrophages, and therefore inhibit insulin resistance. Our results showed that GLP-1 agonist (exendin-4) not only attenuated macrophage infiltration, but also inhibited the macrophage secretion of inflammatory cytokines including TNF-β, IL-6, and IL-1β. Furthermore, we observed that lipopolysaccharide (LPS)-induced macrophage conditioned media could impair insulin-stimulated glucose uptake. This effect was compensated by treatment with the conditioned media from macrophages treated with the combination of LPS and exendin-4. It was also observed that exendin-4 directly inhibited the activation of NF-κB in macrophages. In conclusion, our results indicated that GLP-1 improved inflammatory macrophage-derived insulin resistance by inhibiting NF-κB pathway and secretion of inflammatory cytokines in macrophages. Furthermore, our observations suggested that the anti-inflammatory effect of GLP-1 on macrophages can contribute to GLP-1 analogue therapy of T2D.


Asunto(s)
Humanos , Animales , Ratones , Péptido 1 Similar al Glucagón/farmacología , Mediadores de Inflamación/farmacología , Inflamación/tratamiento farmacológico , Resistencia a la Insulina , Macrófagos/efectos de los fármacos , Péptidos/farmacología , Ponzoñas/farmacología , Tejido Adiposo/metabolismo , Ensayos de Migración Celular , Inflamación/metabolismo , Macrófagos/metabolismo
3.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;48(6): 515-522, 06/2015. graf
Artículo en Inglés | LILACS | ID: lil-748224

RESUMEN

We evaluated the effect of puerarin on spatial learning and memory ability of mice with chronic alcohol poisoning. A total of 30 male C57BL/6 mice were randomly divided into model, puerarin, and control groups (n=10 each). The model group received 60% (v/v) ethanol by intragastric administration followed by intraperitoneal injection of normal saline 30 min later. The puerarin group received intragastric 60% ethanol followed by intraperitoneal puerarin 30 min later, and the control group received intragastric saline followed by intraperitoneal saline. Six weeks after treatment, the Morris water maze and Tru Scan behavioral tests and immunofluorescence staining of cerebral cortex and hippocampal neurons (by Neu-N) and microglia (by Ib1) were conducted. Glutamic acid (Glu) and gamma amino butyric acid (GABA) in the cortex and hippocampus were assayed by high-performance liquid chromatography (HPLC), and tumor necrosis factor (TNF)-α and interleukin (IL)-1β were determined by ELISA. Compared with mice in the control group, escape latency and distance were prolonged, and spontaneous movement distance was shortened (P<0.05) by puerarin. The number of microglia was increased in both the cortex and hippocampal dentate gyrus (P<0.01), and neurons were reduced only in the hippocampal dentate gyrus (P<0.01) in puerarin-treated mice. In the model group, Glu and GABA levels decreased (P<0.05), and Glu/GABA, TNF-α, and IL-1β increased (P<0.01) with puerarin treatment, returning to near normal levels. In conclusion, puerarin protected against the effects of chronic alcohol poisoning on spatial learning and memory ability primarily because of anti-inflammatory activity and regulation of the balance of Glu and GABA.


Asunto(s)
Animales , Masculino , Etanol/envenenamiento , Isoflavonas/uso terapéutico , Aprendizaje por Laberinto/efectos de los fármacos , Trastornos de la Memoria/prevención & control , Fármacos Neuroprotectores/uso terapéutico , Memoria Espacial/efectos de los fármacos , Vasodilatadores/uso terapéutico , Alcoholismo/complicaciones , Cromatografía Líquida de Alta Presión , Corteza Cerebral/química , Corteza Cerebral/efectos de los fármacos , Ensayo de Inmunoadsorción Enzimática , Ácido Glutámico/análisis , Interleucina-1beta/análisis , Isoflavonas/farmacología , Trastornos de la Memoria/inducido químicamente , Trastornos de la Memoria/tratamiento farmacológico , Microglía/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Distribución Aleatoria , Factores de Tiempo , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/análisis , Vasodilatadores/farmacología , Ácido gamma-Aminobutírico/análisis
4.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;48(2): 161-166, 02/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-735848

RESUMEN

Our aim was to investigate the role of chemokines in promoting instability of coronary atherosclerotic plaques and the underlying molecular mechanism. Coronary angiography and intravascular ultrasound (IVUS) were performed in 60 stable angina pectoris (SAP) patients and 60 unstable angina pectoris (UAP) patients. The chemotactic activity of monocytes in the 2 groups of patients was examined in Transwell chambers. High-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), regulated on activation in normal T-cell expressed and secreted (RANTES), and fractalkine in serum were examined with ELISA kits, and expression of MCP-1, RANTES, and fractalkine mRNA was examined with real-time PCR. In the SAP group, 92 plaques were detected with IVUS. In the UAP group, 96 plaques were detected with IVUS. The plaques in the UAP group were mainly lipid 51.04% (49/96) and the plaques in the SAP group were mainly fibrous 52.17% (48/92). Compared with the SAP group, the plaque burden and vascular remodeling index in the UAP group were significantly greater than in the SAP group (P<0.01). Chemotactic activity and the number of mobile monocytes in the UAP group were significantly greater than in the SAP group (P<0.01). Concentrations of hs-CRP, MCP-1, RANTES, and fractalkine in the serum of the UAP group were significantly higher than in the serum of the SAP group (P<0.05 or P<0.01), and expression of MCP-1, RANTES, and fractalkine mRNA was significantly higher than in the SAP group (P<0.05). MCP-1, RANTES, and fractalkine probably promote instability of coronary atherosclerotic plaque.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Angina de Pecho/metabolismo , Quimiocinas/metabolismo , Quimiotaxis/fisiología , Enfermedad de la Arteria Coronaria/metabolismo , Monocitos/metabolismo , Placa Aterosclerótica/fisiopatología , Angina de Pecho/fisiopatología , Proteína C-Reactiva/análisis , /sangre , /sangre , /sangre , Enfermedad de la Arteria Coronaria/fisiopatología , Reacción en Cadena en Tiempo Real de la Polimerasa , Ultrasonografía Intervencional
5.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;48(2): 167-173, 02/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-735851

RESUMEN

High levels of low-density lipoprotein cholesterol (LDL-C) enhance platelet activation, whereas high levels of high-density lipoprotein cholesterol (HDL-C) exert a cardioprotective effect. However, the effects on platelet activation of high levels of LDL-C combined with low levels of HDL-C (HLC) have not yet been reported. We aimed to evaluate the platelet activation marker of HLC patients and investigate the antiplatelet effect of atorvastatin on this population. Forty-eight patients with high levels of LDL-C were enrolled. Among these, 23 had HLC and the other 25 had high levels of LDL-C combined with normal levels of HDL-C (HNC). A total of 35 normocholesterolemic (NOMC) volunteers were included as controls. Whole blood flow cytometry and platelet aggregation measurements were performed on all participants to detect the following platelet activation markers: CD62p (P-selectin), PAC-1 (GPIIb/IIIa), and maximal platelet aggregation (MPAG). A daily dose of 20 mg atorvastatin was administered to patients with high levels of LDL-C, and the above assessments were obtained at baseline and after 1 and 2 months of treatment. The expression of platelets CD62p and PAC-1 was increased in HNC patients compared to NOMC volunteers (P<0.01 and P<0.05). Furthermore, the surface expression of platelets CD62p and PAC-1 was greater among HLC patients than among HNC patients (P<0.01 and P<0.05). Although the expression of CD62p and PAC-1 decreased significantly after atorvastatin treatment, it remained higher in the HLC group than in the HNC group (P<0.05 and P=0.116). The reduction of HDL-C further increased platelet activation in patients with high levels of LDL-C. Platelet activation remained higher among HLC patients regardless of atorvastatin treatment.


Asunto(s)
Adolescente , Niño , Femenino , Humanos , Masculino , Logro , Trastorno por Déficit de Atención con Hiperactividad/psicología , Atención/fisiología , Análisis de Varianza , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Estudios de Cohortes , Escolaridad , Escalas de Valoración Psiquiátrica , Sensibilidad y Especificidad
6.
Artículo en Inglés | IMSEAR | ID: sea-35855

RESUMEN

To evaluate the feasibility of improving external quality assessment (EQA), we set up an experimental EQA survey that included 465 participants in China. During the period of this survey, we checked the quality of the EQA samples, divided the participants into different groups, each laboratory's result was assessed by calculation standard deviation index (SDI). The reference values were determined to evaluate the accuracy for peer groups. The data showed that the stability of the EQA samples was acceptable. Except for WBC count of the Abbott group, the mean, median and reference values for each parameter were very close. We found that the main reason affecting the performance of the participants was not using the reagents. calibrator and QC material recommended by manufacturer. From this survey, we obtain a good reference for future improvement.


Asunto(s)
Calibración , China , Pruebas Hematológicas/instrumentación , Humanos , Laboratorios/normas , Revisión por Expertos de la Atención de Salud , Garantía de la Calidad de Atención de Salud , Estándares de Referencia , Valores de Referencia
7.
Artículo en Inglés | IMSEAR | ID: sea-31088

RESUMEN

The paper describes the endemic situation of schistosomiasis japonica in Fanhu village, Poyang Lake region, China and the effect of the strategy of combining annual mass chemotherapy with health education on schistosomiasis control in the community. The results showed that the prevalence of infection with schistosome reduced form 26.0% in 1992 to 10.7% in 1994, the intensity of infection in residents decreased from 1.92 in 1992 to 0.55 in 1994 and the condition of hepatomegaly, splenomegaly and liver fibrosis also improved after chemotherapy in the individuals in the case prospective study. Moreover, the future strategies of schistosomiasis control in this area have been suggested according to the transmission of schistosomiasis in the lake region and the effect of anti-schistosomiasis control indifferent populations.


Asunto(s)
Adolescente , Adulto , Antiplatelmínticos/uso terapéutico , Niño , China/epidemiología , Enfermedades Endémicas , Femenino , Educación en Salud , Humanos , Masculino , Tamizaje Masivo , Proyectos Piloto , Praziquantel/uso terapéutico , Prevalencia , Evaluación de Programas y Proyectos de Salud , Estudios Prospectivos , Servicios de Salud Rural , Esquistosomiasis Japónica/tratamiento farmacológico , Agua/parasitología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA